This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prostate Testing for Cancer and Treatment (ProtecT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02044172
Recruitment Status : Active, not recruiting
First Posted : January 23, 2014
Last Update Posted : November 14, 2022
Sponsor:
Collaborator:
University of Bristol
Information provided by (Responsible Party):
University of Oxford

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Radical prostatectomy is surgery to remove the entire prostate. Radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells. Sometimes the tumor may not need treatment until it progresses. In this case, active surveillance may be sufficient. It is not yet known which treatment regimen is more effective for localized prostate cancer.

PURPOSE: This randomized phase III trial is studying active monitoring to see how well it works compared with radical prostatectomy or radiation therapy in treating patients with localized prostate cancer.


Condition or disease Intervention/treatment Phase
Prostate Cancer Procedure: Radical prostatectomy Radiation: Conformal radiation therapy Other: Active monitoring Not Applicable

Detailed Description:

OBJECTIVES:

  • To assess survival of patients with localized prostate cancer at 10 years and 15 years after treatment.
  • To investigate disease progression (i.e., biochemical and clinical), treatment complications, and lower urinary tract symptoms in these patients.
  • To investigate the psychosocial impact of cancer detection and treatment on these patients, including generic health status, quality of life, and sexual function.
  • To estimate the resource use and costs of detection, treatment, and follow-up.
  • To compare costs and outcomes of treatment in terms of survival and health-related quality of life.
  • To collect samples suitable for basic science research (ProMPT study).

OUTLINE: This is a multicenter study. Patients are stratified by age (50-55 vs 56-59 vs 60-65 vs 66-69 years), Gleason score (6, 7, 8-10), and average result of recruitment and first biopsy prostate-specific antigen (PSA) tests (< 6 vs 6-9.9 vs ≥ 10 ng/mL). Patients are randomized or select a treatment to be followed up in a cohort study.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82849 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer
Actual Study Start Date : June 1, 2001
Actual Primary Completion Date : November 14, 2020
Estimated Study Completion Date : March 31, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Radical prostatectomy
Radical prostatectomy
 Procedure: Radical prostatectomy
radical prostatectomy
Active Comparator: Conformal radiation therapy
Conformal radiation therapy External beam radiation therapy
 Radiation: Conformal radiation therapy
Conformal radiation therapy, external beam
Active Comparator: Active monitoring
Active monitoring of prostate specific antigen levels and disease surveillance
 Other: Active monitoring
Active monitoring of Prostate specific antigen levels and disease surveillance


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Disease specific mortality [ Time Frame: Median 15 years follow up ]

Secondary Outcome Measures :
  1. Overall survival [ Time Frame: Median 15 years ]
  2. Disease progression [ Time Frame: Median 15 years ]
    Metastases

  3. Treatment complications [ Time Frame: Median 15 years ]
  4. General health status [ Time Frame: Median 15 years ]
  5. Psychological state [ Time Frame: Median 15 years ]
  6. Symptoms [ Time Frame: Median 15 years ]
  7. Sexual function [ Time Frame: Median 15years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 69 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Fit for the treatments and estimates life expectancy of 10 years Registration with eligible primary care practice

Exclusion Criteria:

Unable to give written informed consent. Concomitant or past malignancy.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02044172


Locations
Layout table for location information
United Kingdom
Queen Elizabeth Hospital
Birmingham, United Kingdom
Southmead Hospital
Bristol, United Kingdom
Addenbrokes' Hospital
Cambridge, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
Western General Hospital
Edinburgh, United Kingdom
Leicester General Hospital
Leicester, United Kingdom
Freeman Hospital
Newcastle, United Kingdom
Royal Hallamshire Hospital
Sheffield, United Kingdom
Sponsors and Collaborators
University of Oxford
University of Bristol
Investigators
Layout table for investigator information
Principal Investigator: Freddie C Hamdy University of Oxford
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT02044172    
Obsolete Identifiers: NCT00632983
Other Study ID Numbers: HTA96/20/99
20141297 ( Registry Identifier: ISRCTN )
First Posted: January 23, 2014    Key Record Dates
Last Update Posted: November 14, 2022
Last Verified: November 2022
Keywords provided by University of Oxford:
Prostate cancer
Treatment
Screening
 Surgery
Radiotherapy
Active monitoring
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases